Safety of fluralaner,a novel systemic antiparasitic drug,in MDR1(-/-) Collies after oral administration

Background: fluralaner is a novel systemic ectoparasiticide for dogs providing long-acting flea- and tick-control after a single oral dose. this study investigated the safety of oral administration of fluralaner at 3 times the highest expected clinical dose to multi drug resistance protein 1 (mdr1(-/-)) gene defect collies. methods. sixteen collies homozygous for the mdr1 deletion mutation were included in the study. eight collies received fluralaner chewable tablets once at a dose of 168 mg/kg; eight sham dosed collies served as controls. all collies were clinically observed until 28 days following treatment. results: no adverse events were observed subsequent to fluralaner treatment of mdr1(-/-) collies at three times the highest expected clinical dose. conclusions: fluralaner chewable tablets are well tolerated in mdr1(-/-) collies following oral administration. © 2014 walther et al.; licensee biomed central ltd.